EUVIMEDEUVIMED entdecken
Crossref

Oxopyrrolidine–Acylhydrazone Scaffolds as Dual Inducers of Autophagy and Ferroptosis in the Breast Cancer via JNK/Beclin‐1/GPX4 Regulation

Monisha Yadav H S iD, Min Hee Yang, Omantheswara Nagaraja, Santosh L Gaonkar iD, Shreeja Basappa, Mahendra Madegowda iD, Vladimir N Nikolenko iD, Kanchugarakoppal S Rangappa iD, Narasimha M Beeraka iD, Basappa Basappa iD, Kwang Seok Ahn iD

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 03.11.2026. Verfasst von Monisha Yadav H S und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore, Karnataka, India. Hauptthemen laut MEDLINE: Autophagy, Ferroptosis, Breast Neoplasms, Pyrrolidines. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Karnataka Science and Technology Promotion Society (KSTePS), DST, Govt. of Karnataka, Vision Group on Science and Technology (VGST), Govt. of Karnataka, National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autophagy and ferroptosis are evolutionarily conserved stress‐response pathways that critically regulate tumor progression and therapeutic responsiveness. In breast cancer, the autophagy initiator Beclin‐1 acts as a haploinsufficient tumor suppressor, whereas susceptibility to ferroptosis is largely governed by the GPX4–SLC7A11–TFRC redox axis. Therapeutic strategies capable of coordinately modulating these pathways remain largely unexplored. This study aimed to identify novel redox‐active anticancer agents by designing and synthesizing a focused library of oxopyrrolidine‐tethered N ‐acylhydrazone derivatives PCH (01–17). The lead compound, PCH‐03, was investigated to elucidate its ability to induce ROS‐dependent JNK3 signaling and coordinate autophagy–ferroptosis crosstalk in breast cancer cells through integrated computational and experimental analyses. Computational investigations, including molecular docking, molecular dynamics simulations, and frontier molecular orbital (FMO) and molecular electrostatic potential (MESP) analyses, were performed to evaluate the structural compatibility of PCH‐03 with the conserved JNK kinase domain and its electronic properties. Biological activity was assessed in four human breast cancer cell lines (MCF‐7, SK‐BR‐3, BT‐474, and MDA‐MB‐231) and normal breast epithelial MCF‐10A cells using MTT assays, mitochondrial membrane potential analysis, intracellular ROS measurement, immunocytochemical analysis of LC3 and GPX4, MDC staining, flow cytometry, and intracellular Fe 2+ quantification. Western blotting, together with chloroquine‐mediated autophagic flux analysis and p62/SQSTM1 evaluation, was used to characterize autophagy, while ferroptosis involvement was validated using ferrostatin‐1 (Fer‐1). Pharmacological inhibition with SP600125 was employed to investigate the contribution of JNK3 signaling. PCH‐03 inhibited the viability of breast cancer cells with IC 50 values of 35.24 μM in MCF‐7, 35.46 μM in SK‐BR‐3, 50.81 μM in BT‐474, and 35.71 μM in MDA‐MB‐231 cells, whereas a higher IC 50 value of 141.85 μM was observed in normal breast epithelial MCF‐10A cells, indicating preferential cytotoxicity toward breast cancer cells. PCH‐03 induced intracellular ROS accumulation, mitochondrial membrane depolarization, and oxidative stress, accompanied by activation of JNK phosphorylation. The compound increased Atg7, Beclin‐1 and phosphorylated Beclin‐1 (p‐Beclin‐1), and LC3‐II expression, and chloroquine‐mediated flux assays together with p62/SQSTM1 analysis confirmed activation of functional autophagic flux. Concurrently, PCH‐03 suppressed GPX4 and SLC7A11, increased TFRC expression, and promoted intracellular Fe 2+ accumulation, consistent with ferroptosis induction. SP600125 significantly attenuated autophagy‐associated signaling and partially restored GPX4 expression, supporting the involvement of JNK3 signaling in mediating autophagy–ferroptosis crosstalk, whereas ferrostatin‐1 partially rescued cell viability, reduced iron accumulation, and attenuated JNK3 phosphorylation, indicating that ferroptosis functionally contributes to PCH‐03‐induced cell death alongside JNK3 pathway activation. PCH‐03 is a novel oxopyrrolidine‐ N ‐acylhydrazone derivative that exerts antibreast cancer activity by disrupting redox homeostasis and promoting coordinated autophagy and ferroptosis with the contribution of ROS‐dependent JNK signaling. Although additional genetic validation is warranted to define isoform‐specific JNK regulation, these findings identify PCH‐03 as a promising lead scaffold for developing anticancer therapeutics that coordinately modulate autophagy and ferroptosis to potentially overcome therapeutic resistance in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutophagyFerroptosisBreast NeoplasmsPyrrolidinesHydrazonesAntineoplastic AgentsHumansFemaleBeclin-1Phospholipid Hydroperoxide Glutathione PeroxidaseCell Line, TumorMolecular Docking SimulationReactive Oxygen Species

Stichwörter der Autor:innen

Beclin‐1GPX4JNK signalingN‐acylhydrazone derivativesPCH‐03autophagybreast cancerferroptosisoxopyrrolidineredox homeostasis

Substanzen

Beclin-1PyrrolidinesHydrazonesAntineoplastic AgentsPhospholipid Hydroperoxide Glutathione PeroxidaseBECN1 protein, humanReactive Oxygen Species

Autor:innen und Institutionen

  • Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore, Karnataka, India.
  • Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Studies in Physics, University of Mysore, Mysore, Karnataka, India.
  • Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, India.
  • Department of Chemistry, BITS-Pilani Hyderabad Campus, Jawahar Nagar, Medchal, India.
  • Department of Studies in Physics, University of Mysore, Manasagangotri, Mysore, India.

ORCID-Profile: Monisha Yadav H S, Santosh L Gaonkar, Mahendra Madegowda, Vladimir N Nikolenko, Kanchugarakoppal S Rangappa, Narasimha M Beeraka, Basappa Basappa, Kwang Seok Ahn

Förderung

  • Karnataka Science and Technology Promotion Society (KSTePS), DST, Govt. of Karnataka
  • Vision Group on Science and Technology (VGST), Govt. of Karnataka
  • National Research Foundation of Korea (NRF)
  • Korean government (MSIP)

Zitieren

APA

H S, M. Y., Yang, M. H., Nagaraja, O., Gaonkar, S. L., Basappa, S., Madegowda, M., Nikolenko, V. N., Rangappa, K. S., Beeraka, N. M., Basappa, B., & Ahn, K. S. (2026). Oxopyrrolidine–Acylhydrazone Scaffolds as Dual Inducers of Autophagy and Ferroptosis in the Breast Cancer via JNK/Beclin‐1/GPX4 Regulation. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70401

Vancouver

H S MY, Yang MH, Nagaraja O, Gaonkar SL, Basappa S, Madegowda M, et al. Oxopyrrolidine–Acylhydrazone Scaffolds as Dual Inducers of Autophagy and Ferroptosis in the Breast Cancer via JNK/Beclin‐1/GPX4 Regulation. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70401

BibTeX
@article{HS2026,
  author = {H S, Monisha Yadav and Yang, Min Hee and Nagaraja, Omantheswara and Gaonkar, Santosh L and Basappa, Shreeja and Madegowda, Mahendra and Nikolenko, Vladimir N and Rangappa, Kanchugarakoppal S and Beeraka, Narasimha M and Basappa, Basappa and Ahn, Kwang Seok},
  title = {Oxopyrrolidine–Acylhydrazone Scaffolds as Dual Inducers of Autophagy and Ferroptosis in the Breast Cancer via JNK/Beclin‐1/GPX4 Regulation},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70401}
}
Kostenlos starten →